Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Intra-Cellular Ther (ITCI)

Intra-Cellular Ther (ITCI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,794,911
  • Shares Outstanding, K 81,342
  • Annual Sales, $ 22,810 K
  • Annual Income, $ -227,010 K
  • 60-Month Beta 1.29
  • Price/Sales 123.01
  • Price/Cash Flow N/A
  • Price/Book 5.08
Trade ITCI with:

Options Overview

Details
  • Implied Volatility 64.99%
  • Historical Volatility 33.73%
  • IV Percentile 21%
  • IV Rank 24.77%
  • IV High 100.48% on 01/27/21
  • IV Low 53.31% on 05/26/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 425
  • Volume Avg (30-Day) 241
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 5,946
  • Open Int (30-Day) 3,004

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.89
  • Number of Estimates 3
  • High Estimate -0.84
  • Low Estimate -0.95
  • Prior Year -0.79
  • Growth Rate Est. (year over year) -12.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.44 +20.79%
on 08/20/21
35.27 -2.58%
on 09/03/21
+3.99 (+13.14%)
since 08/17/21
3-Month
28.40 +20.99%
on 08/12/21
44.80 -23.30%
on 06/23/21
-8.80 (-20.39%)
since 06/17/21
52-Week
22.92 +49.95%
on 10/29/20
44.80 -23.30%
on 06/23/21
+3.39 (+10.95%)
since 09/17/20

Most Recent Stories

More News
Intra-Cellular Therapies to Present at the Canaccord Genuity 41st Annual Growth Conference

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that...

ITCI : 34.36 (-0.41%)
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates

Intra-Cellular (ITCI) delivered earnings and revenue surprises of -7.59% and 8.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ITCI : 34.36 (-0.41%)
Intra-Cellular: Q2 Earnings Snapshot

NEW YORK (AP) _ Intra-Cellular Therapies Inc. (ITCI) on Monday reported a loss of $68.7 million in its second quarter.

ITCI : 34.36 (-0.41%)
Intra-Cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update

CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a PDUFA target action date of December 17, 2021.

ITCI : 34.36 (-0.41%)
Will Intra-Cellular Therapies (ITCI) Report Negative Q2 Earnings? What You Should Know

Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ITCI : 34.36 (-0.41%)
Intra-Cellular Therapies to Host Second Quarter 2021 Financial Results Conference Call and Webcast

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that...

ITCI : 34.36 (-0.41%)
This Could Help Drive Multi-Billion-Growth for Digital Health Companies

Demand for digital health technology is only gaining momentum. In fact, according to an Accenture ...

NUMI.VN : 0.770 (-6.10%)
LKYSF : 0.6092 (-5.80%)
MYCO.CN : 0.400 (-6.98%)
MYCOF : 0.3030 (+9.82%)
SAVA : 48.51 (+10.38%)
ITCI : 34.36 (-0.41%)
AIMLF : 0.5801 (+1.65%)
AIML.CN : 0.750 (unch)
CAPLYTA(R) (lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology

Pooled analysis of 3 randomized, double-blind, pacebo-cotrolled trials supports the safety and the distinct and favorable tolerability profile of lumateperone 42 mg

ITCI : 34.36 (-0.41%)
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that...

ITCI : 34.36 (-0.41%)
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 19.75% and 0.88%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

ITCI : 34.36 (-0.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular...

See More

Key Turning Points

3rd Resistance Point 35.85
2nd Resistance Point 35.37
1st Resistance Point 34.86
Last Price 34.36
1st Support Level 33.88
2nd Support Level 33.40
3rd Support Level 32.89

See More

52-Week High 44.80
Fibonacci 61.8% 36.44
Last Price 34.36
Fibonacci 50% 33.86
Fibonacci 38.2% 31.28
52-Week Low 22.92

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar